Running chemotherapeutic drug screens on tumor biopsies ex vivo has the potential to increase patient survival by personally matching them to the drug which is the most effective against their particular tumor.
Stanford researchers have developed a quantitative, noninvasive, and early predictor of viability at the early embryo and oocyte stage using mechanical biomarkers.